23andMe pockets $22M in new venture round

Despite some harsh recent criticism from government regulators on the usefulness and accuracy of its controversial consumer gene tests, the high-profile 23andMe scored a $22 million Series C round. Johnson & Johnson Development Corporation led the round with contributions from New Enterprise Associates and Google Ventures.

"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make health care research and health care delivery more efficient," said Anne Wojcicki, chief executive officer of 23andMe and wife of Google co-founder Sergey Brin.

Over the summer 23andMe along with Navigenics and other gene analysis outfits drew some unwelcome attention from the GAO, which concluded that they were making some poor health predictions based on their tests. 23andMe called the report "flawed." Evidently their financial backers agree.

- here's the 23andMe release for more info

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.